Regulatory Authorization Italian Medicines Agency Approves New Line at Dipharma’s cGMP Pilot Plant

Source: Press release Dipharma |

Related Vendors

Dipharma’s new production line at the cGMP pilot plant will help the company to double its capacity to process projects in the fields of generics and CDMO. Located in the firm’s Mereto di Tomba facility in Italy, the pilot plant can produce batches ranging from 5 to 50 kilograms.

Dipharma’s new cGMP pilot plant line is located in the firm’s Mereto di Tomba facility in Italy.
Dipharma’s new cGMP pilot plant line is located in the firm’s Mereto di Tomba facility in Italy.
(Source: Dipharma)

Milan/Italy – Dipharma, a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active Pharmaceutical Ingredients, recently announced that the Italian Medicines Agency (Aifa) approved the brand-new production line at the cGMP pilot plant suite, located in its facility of Mereto di Tomba (Italy).

The expansion includes a further two glass-lined and two stainless steel reactors, along with a Hastelloy C-22 filter-dryer having a continuous liner discharge, featuring a full closed-system handling approach. With this state-of-the-art investment, Dipharma doubles its capacity to process projects for customers, both in the generics and CDMO arena, while enhancing operational safety and isolation technologies.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Already fully operational, the current pilot plant configuration consists of two independent production lines and can produce batches ranging from 5 to 50 kilograms under the most rigorous cGMP conditions, providing flexibility to develop the most effective chemistry prior to moving to production scale.

“We have experienced an unprecedented increase in demand for our services,” said Jorge Nogueira, Chief Executive Officer of Dipharma Francis, “particularly for small-scale projects, and the regulatory approval of our new pilot line enables us to better fulfill our customers’ requests and expectations, expanding our network capabilities and reinforcing our integrated services to materialize their projects. This expansion is the latest in a series of strategic investments we are planning in our facilities at all scales to enhance Dipharma’s competitiveness and offer to our international pharma clients a full partnership all the way from preclinical to commercial”.

(ID:48647610)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent